8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Lyell Immunopharma, Inc.(LYEL)Earnings, Financials & Key Ratios
LYEL•NASDAQ
Price updated Jun 19, 2026
AboutLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$36K-41.0%
- EBITDA-$192M+43.3%
- Net Income-$274M+20.0%
- EPS (Diluted)-16.06-1126.0%
- Gross Margin-31952.78%-32052.8%
- EBITDA Margin-533986.11%+3.9%
- Operating Margin-566038.89%+3.8%
- Net Margin-762355.56%-35.6%
- ROE-86.98%-31.6%
LYEL Key Insights
Lyell Immunopharma, Inc. (LYEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Sales declining 65.9% over 5 years
- ✗Shares diluted 30.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LYEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LYEL Price & Volume
Lyell Immunopharma, Inc. (LYEL) stock price & volume — 10-year historical chart
Loading chart...
LYEL Growth Metrics
Lyell Immunopharma, Inc. (LYEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-65.85%
3 Years-92.48%
TTM-52.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-919.69%
Return on Capital
10 Years-34.2%
5 Years-37.97%
3 Years-49.61%
Last Year-56%
LYEL Recent Earnings
Lyell Immunopharma, Inc. (LYEL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$1.10+60.4%
$2.78
Rev
$2,000-33.3%
$3,000
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$7.68-257.2%
$2.15
Rev
$6,000-60.7%
$15,250
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.13+24.2%
$2.81
Rev
$15,000
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$2.89+23.9%
$3.80
Rev
$8,000+100.0%
$4,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.10vs $2.78+60.4% | $2,000vs $3,000-33.3% |
| Q2 2026 | Mar 12, 2026 | $7.68vs $2.15-257.2% | $6,000vs $15,250-60.7% |
| Q4 2025 | Nov 12, 2025 | $2.13vs $2.81+24.2% | $15,000 |
| Q3 2025 | Aug 12, 2025 | $2.89vs $3.80+23.9% | $8,000vs $4,000+100.0% |
Based on last 12 quarters of dataView full earnings history →
LYEL Peer Comparison
Lyell Immunopharma, Inc. (LYEL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALKT | 1.57B | 14.68 | -31.91 | 32.89% | -10.55% | -13.96% | 0.98 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare LYEL vs Peers
Lyell Immunopharma, Inc. (LYEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LYEL Income Statement
Lyell Immunopharma, Inc. (LYEL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 657K | 7.76M | 10.65M | 84.68M | 130K | 61K | 36K | 31K |
Revenue Growth % | - | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -40.98% | -52.31% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 11.54M | 2.33M |
COGS % of Revenue | - | - | - | - | - | - | 32052.78% | - |
Gross Profit | 657K▲ 0% | 7.76M▲ 1080.5% | 10.65M▲ 37.3% | 84.68M▲ 695.1% | 130K▼ 99.8% | 61K▼ 53.1% | -11.5M▼ 18957.4% | -2.3M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | -31952.78% | -7422.58% |
Gross Profit Growth % | - | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -18957.38% | - |
Operating Expenses | 102.75M | 219.69M | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M | 189.56M |
OpEx % of Revenue | 15638.66% | 2832.56% | 2116.68% | 320.89% | 190106.15% | 588222.95% | 534086.11% | - |
Selling, General & Admin | 39.15M | 46.88M | 89.06M | 117.31M | 66.98M | 52.04M | 45.13M | 40.64M |
SG&A % of Revenue | 5959.06% | 604.45% | 836.22% | 138.52% | 51525.38% | 85313.11% | 125375% | - |
Research & Development | 63.59M | 182.24M | 138.69M | 159.19M | 182.94M | 171.6M | 158.68M | 151.83M |
R&D % of Revenue | 9679.6% | 2349.7% | 1302.28% | 187.98% | 140726.92% | 281316.39% | 440763.89% | - |
Other Operating Expenses | 0 | -9.43M | -2.32M | -4.75M | -2.79M | 135.17M | -11.54M | -2M |
Operating Income | -102.09M▲ 0% | -211.94M▼ 107.6% | -214.78M▼ 1.3% | -187.06M▲ 12.9% | -247.01M▼ 32.0% | -358.75M▼ 45.2% | -203.77M▲ 43.2% | -191.86M▲ 0% |
Operating Margin % | -15538.66% | -2732.56% | -2016.68% | -220.89% | -190006.15% | -588122.95% | -566038.89% | -618909.68% |
Operating Income Growth % | - | -107.6% | -1.34% | 12.91% | -32.05% | -45.24% | 43.2% | - |
EBITDA | -100.83M | -207.64M | -201.15M | -169.04M | -226.76M | -339.12M | -192.24M | -181.43M |
EBITDA Margin % | -15347.49% | -2677.19% | -1888.75% | -199.61% | -174429.23% | -555940.98% | -533986.11% | -585264.52% |
EBITDA Growth % | - | -105.93% | 3.13% | 15.96% | -34.15% | -49.55% | 43.31% | 47.03% |
D&A (Non-Cash Add-back) | 1.26M | 4.29M | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M | 10.43M |
EBIT | -102.09M | -219.72M | -214.78M | -187.06M | -247.01M | -220.27M | -203.77M | -192.01M |
Net Interest Income | 8.12M | 5.94M | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M | 11.41M |
Interest Income | 8.12M | 5.94M | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M | 11.41M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -27.29M | 7.46M | -35.44M | 3.94M | 12.38M | 15.76M | -70.67M | -54.54M |
Pretax Income | -129.38M▲ 0% | -204.47M▼ 58.0% | -250.22M▼ 22.4% | -183.12M▲ 26.8% | -234.63M▼ 28.1% | -342.99M▼ 46.2% | -274.45M▲ 20.0% | -246.41M▲ 0% |
Pretax Margin % | -19692.09% | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -129.38M▲ 0% | -204.47M▼ 58.0% | -250.22M▼ 22.4% | -183.12M▲ 26.8% | -234.63M▼ 28.1% | -342.99M▼ 46.2% | -274.45M▲ 20.0% | -246.41M▲ 0% |
Net Margin % | -19692.09% | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
Net Income Growth % | - | -58.04% | -22.37% | 26.82% | -28.13% | -46.18% | 19.98% | 26.34% |
Net Income (Continuing) | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M | -274.45M | -246.41M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.53▲ 0% | -0.84▼ 59.4% | -1.03▼ 22.2% | -0.74▲ 28.1% | -0.93▼ 26.1% | -1.31▼ 40.1% | -16.06▼ 1126.0% | -11.26▲ 0% |
EPS Growth % | - | -59.42% | -22.16% | 28.1% | -26.14% | -40.14% | -1125.95% | -919.69% |
EPS (Basic) | -0.53 | -0.84 | -1.03 | -0.74 | -0.93 | -1.31 | -16.06 | - |
Diluted Shares Outstanding | 12.33M | 12.33M | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M | 21.88M |
Basic Shares Outstanding | 12.33M | 12.33M | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M | 21.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LYEL Balance Sheet
Lyell Immunopharma, Inc. (LYEL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 440.26M | 617.55M | 626.29M | 651.29M | 554.69M | 379.59M | 260.94M | 267.3M |
Cash & Short-Term Investments | 436.05M | 612.62M | 614.79M | 640.15M | 546.22M | 370.53M | 247.22M | 254.02M |
Cash Only | 96.67M | 140.41M | 293.83M | 123.55M | 145.65M | 105.6M | 60.18M | 90.77M |
Short-Term Investments | 339.38M | 472.21M | 320.97M | 516.6M | 400.58M | 264.93M | 187.04M | 163.25M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 11.14M | 8.46M | 9.07M | 13.72M | 13.28M |
Total Non-Current Assets | 115.37M | 290.73M | 501.12M | 286.27M | 195.34M | 111.27M | 79.11M | 83.32M |
Property, Plant & Equipment | 43.7M | 124.06M | 166.64M | 166.26M | 142.32M | 72.94M | 53.64M | 50.55M |
Fixed Asset Turnover | 0.02x | 0.06x | 0.06x | 0.51x | 0.00x | 0.00x | 0.00x | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 68.98M | 163.44M | 330.53M | 115.04M | 48.51M | 32.01M | 19M | 96.06M |
Other Non-Current Assets | 2.68M | 3.23M | 3.95M | 4.96M | 4.52M | 6.31M | 6.47M | 13.77M |
Total Assets | 555.63M▲ 0% | 908.28M▲ 63.5% | 1.13B▲ 24.1% | 937.56M▼ 16.8% | 750.03M▼ 20.0% | 490.86M▼ 34.6% | 340.05M▼ 30.7% | 350.63M▲ 0% |
Asset Turnover | 0.00x | 0.01x | 0.01x | 0.09x | 0.00x | 0.00x | 0.00x | 0.00x |
Asset Growth % | - | 63.47% | 24.13% | -16.84% | -20% | -34.55% | -30.72% | -124.33% |
Total Current Liabilities | 22.05M | 49.28M | 46.74M | 37.03M | 34.52M | 53.79M | 49.41M | 36.95M |
Accounts Payable | 2.84M | 9.4M | 3.21M | 3.92M | 4.82M | 5.37M | 2.89M | 5.47M |
Days Payables Outstanding | - | - | - | - | - | - | 91.51 | 559.86 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 4.51M | 6.09M | 4.99M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10.58M | 15.33M | 28.25M | 22.16M | 8.79M | 22.72M | 46.52M | 31.48M |
Current Ratio | 19.97x | 12.53x | 13.40x | 17.59x | 16.07x | 7.06x | 5.28x | 7.23x |
Quick Ratio | 19.97x | 12.53x | 13.40x | 17.59x | 16.07x | 7.06x | 5.28x | 7.23x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 125.53M | 140.56M | 150.88M | 67.28M | 60.56M | 54.25M | 42.44M | 40.01M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.49M |
Capital Lease Obligations | 27.13M | 50.96M | 66.65M | 63.17M | 56.89M | 50.99M | 41.92M | 132.8M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 532K | 4.57M | 4.11M | 3.66M | 3.25M | 517K | 527K |
Total Liabilities | 147.58M | 189.84M | 197.62M | 104.31M | 95.08M | 108.03M | 91.85M | 76.96M |
Total Debt | 27.47M | 54.57M | 67.82M | 67.7M | 63.17M | 58.97M | 41.92M | 39.49M |
Net Debt | -69.2M | -85.83M | -226.01M | -55.85M | -82.48M | -46.63M | -18.26M | -51.28M |
Debt / Equity | 0.07x | 0.08x | 0.07x | 0.08x | 0.10x | 0.15x | 0.17x | 0.14x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.22x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.28x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 408.06M▲ 0% | 718.44M▲ 76.1% | 929.79M▲ 29.4% | 833.25M▼ 10.4% | 654.95M▼ 21.4% | 382.82M▼ 41.5% | 248.2M▼ 35.2% | 273.67M▲ 0% |
Equity Growth % | - | 76.06% | 29.42% | -10.38% | -21.4% | -41.55% | -35.17% | -139.06% |
Book Value per Share | 33.10 | 58.27 | 76.61 | 67.45 | 52.19 | 29.28 | 14.52 | 12.51 |
Total Shareholders' Equity | 408.06M | 718.44M | 929.79M | 833.25M | 654.95M | 382.82M | 248.2M | 273.67M |
Common Stock | 1K | 2K | 24K | 25K | 25K | 29K | 2K | 2K |
Retained Earnings | -129.67M | -334.14M | -584.36M | -767.48M | -1B | -1.35B | -1.62B | -1.64B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 454K | 256K | -1.62M | -7.6M | -94K | 291K | 242K | -9K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYEL Cash Flow Statement
Lyell Immunopharma, Inc. (LYEL) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | 39.47M | -160.87M | -126.25M | -169.56M | -163.69M | -162.39M | -150.02M | -133.8M |
Operating CF Margin % | 6008.22% | -2074.19% | -1185.44% | -200.22% | -125918.46% | -266219.67% | -416733.33% | - |
Operating CF Growth % | - | -507.54% | 21.52% | -34.3% | 3.46% | 0.79% | 7.62% | 89.37% |
Net Income | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M | -274.45M | -246.41M |
Depreciation & Amortization | 1.26M | 4.29M | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M | 10.43M |
Stock-Based Compensation | 15.73M | 33.26M | 62.2M | 0 | 47.08M | 33.14M | 41.83M | 35.8M |
Deferred Taxes | -1.52M | 0 | 39.51M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 42.57M | 6.38M | 4.62M | 79.11M | 183K | 130.94M | 80.95M | 67.8M |
Working Capital Changes | 110.81M | -336K | 4.01M | -82.02M | 3.42M | -3.12M | -9.89M | -1.42M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.71M | -278K | 91K | 667K | 1.46M | -3.23M | -2.34M | 1.7M |
Cash from Investing | -422.43M | -273.52M | -121.57M | -11.54M | 184.05M | 122.42M | 54.1M | 2.01M |
Capital Expenditures | -16.05M | -51.48M | -65.5M | -24.28M | -2.69M | -464K | -780K | -623K |
CapEx % of Revenue | 2442.47% | 663.76% | 615.06% | 28.67% | 2066.15% | 760.66% | 2166.67% | 2009.68% |
Acquisitions | 0 | 0 | 673.47M | 0 | 0 | -31.35M | -41.2M | 263K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -610.84M | 0 | -673.47M | 0 | 0 | 0 | -18.9M | -41.17M |
Cash from Financing | 351.16M | 476.79M | 401.24M | 10.63M | 1.74M | 1.33M | 50.41M | 102.13M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 351.16M | 476.42M | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M | 102.13M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -185K | -11.81M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 373K | 9.44M | -461K | -457K | -76K | -1K | -2K |
Net Change in Cash | -31.8M▲ 0% | 42.4M▲ 233.3% | 153.42M▲ 261.8% | -170.27M▼ 211.0% | 22.09M▲ 113.0% | -38.64M▼ 274.9% | -45.52M▼ 17.8% | -29.66M▲ 0% |
Free Cash Flow | 23.43M▲ 0% | -212.35M▼ 1006.5% | -191.75M▲ 9.7% | -193.83M▼ 1.1% | -166.38M▲ 14.2% | -162.86M▲ 2.1% | -150.8M▲ 7.4% | -134.42M▲ 0% |
FCF Margin % | 3565.75% | -2737.94% | -1800.5% | -228.89% | -127984.62% | -266980.33% | -418900% | -433609.68% |
FCF Growth % | - | -1006.45% | 9.7% | -1.08% | 14.16% | 2.12% | 7.4% | 23.54% |
FCF per Share | 1.90 | -17.22 | -15.80 | -15.69 | -13.26 | -12.46 | -8.82 | -6.14 |
FCF Conversion (FCF/Net Income) | -0.31x | 0.79x | 0.50x | 0.93x | 0.70x | 0.47x | 0.55x | 0.55x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYEL Key Ratios
Lyell Immunopharma, Inc. (LYEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -36.3% | -30.36% | -20.77% | -31.53% | -66.1% | -86.98% | -85.71% |
Return on Invested Capital (ROIC) | -32.72% | -24.11% | -18.94% | -27.45% | -59.22% | -53.99% | -60.12% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | -31952.78% | -7422.58% |
Net Margin | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
Debt / Equity | 0.08x | 0.07x | 0.08x | 0.10x | 0.15x | 0.17x | 0.14x |
FCF Conversion | 0.79x | 0.50x | 0.93x | 0.70x | 0.47x | 0.55x | 0.55x |
Revenue Growth | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -40.98% | -52.31% |
Related:LYEL Dividend History·LYEL Revenue History·LYEL Price History·LYEL P/E History·LYEL Financial Ratios·LYEL Institutional Holders
LYEL SEC Filings & Documents
Lyell Immunopharma, Inc. (LYEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
LYEL Frequently Asked Questions
Lyell Immunopharma, Inc. (LYEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lyell Immunopharma, Inc. (LYEL) reported $0.0M in revenue for fiscal year 2025. This represents a 95% decrease from $0.7M in 2019.
Lyell Immunopharma, Inc. (LYEL) saw revenue decline by 41.0% over the past year.
Lyell Immunopharma, Inc. (LYEL) reported a net loss of $246.4M for fiscal year 2025.
Dividend & Returns
Lyell Immunopharma, Inc. (LYEL) has a return on equity (ROE) of -87.0%. Negative ROE indicates the company is unprofitable.
Lyell Immunopharma, Inc. (LYEL) had negative free cash flow of $134.4M in fiscal year 2025, likely due to heavy capital investments.